Unveiling the Impact of MRC1 on Immune Infiltration and Patient's Prognosis: A Pan-Cancer Analysis Based on Single-Cell and Bulk Sequencing
DOI: https://doi.org/10.2147/ijgm.s461144
IF: 2.145
2024-06-04
International Journal of General Medicine
Abstract:Zhiwei Wu, Changhao Huang Department of Organ Transplantation, XiangYa Hospital of Central South University, Changsha, People's Republic of China Correspondence: Changhao Huang, Email Purpose: Mannose receptor C-type 1 (MRC1) is an endocytic lectin receptor primarily expressed in macrophages, dendritic cells, and some endothelial cells. However, the role of MRC1 in cancers remains unclear. Methods: We analyzed MRC1 expression using The Cancer Genome Atlas (TCGA), Genotype-Tissue Expression (GTEx), Cancer Cell Line Encyclopedia (CCLE), and single-cell datasets. We systematically explored the prognostic implications and diagnostic value of MRC1. Immune-related indicators, including immune cells, immune scores, and immune checkpoint molecules, were used to estimate their correlation with MRC1 expression. Finally, we explored its potential ties to immunotherapy success markers such as tumor mutation burden and DNA repair genes. Results: MRC1 showed both pro- and anti-tumor leanings depending on the cancer types. High levels correlated with poorer outcomes in six cancers but improved prognosis in some cancers like glioblastoma multiforme. This trend extended to the immune arena, where MRC1 intertwined with diverse immune parameters, suggesting its influence on affecting the tumor's immunological landscape. Intriguingly, its expression positively associated with factors favoring immunotherapy efficacy while negatively correlating with some potential barriers. Single-cell analysis pinpointed a specific link between MRC1 and DNA damage/repair pathways in breast cancer. Conclusion: Our study provides a comprehensive landscape of MRC1 levels and diverse regulatory patterns in different cancers, deepening the understanding of MRC1's roles in tumorigenesis and immunity. Keywords: MRC1, biomarker, immunotherapy, single-cell, pan-cancer analysis Immune checkpoint inhibitor (ICI) treatment, including monoclonal antibodies targeting programmed death-ligand 1, programmed death 1, and CTL-associated protein 4, is widely used to treat advanced cancer. However, many cancers do not respond to existing ICIs. Some patients with cancers considered to respond well to ICIs may not benefit from immunotherapy. In recent years, predictive biomarkers have been proposed to distinguish whether tumors are responsive to ICI treatment. Some of these markers, such as tumor mutation burden (TMB) and tumor-infiltrating lymphocytes (TILs), have been successfully applied in some tumor immunotherapy responsiveness predictions. 1–3 Nevertheless, due to the heterogeneity of tumors, these biomarkers can only be used in limited cancer types. The identification of more precise biomarkers of ICI treatment through pan-cancer analysis will promote the progression of immunotherapy research. Antigen presentation is a crucial process in cellular immunity. The macrophage mannose receptor (mannose receptor C-type 1, MRC1, or CD206) plays an important role in antigen presentation and the induction of immune response. 4 MRC1 is an endocytic lectin receptor expressed primarily in macrophages, dendritic cells, and some endothelial cells. A previous study demonstrated that MRC1 promotes the activation of tumor antigen-specific CD4+ and CD8+ T cell. 5 Another study revealed that using a peptide conjugated to an antibody against MRC1 could reduce cross-presentation. 6 Tumor-related macrophages have been found to polarize to a subset of cells with M2-like properties, compromising antitumor immunity—a phenomenon that is associated with poor prognosis in animal models and human patients. Notably, MRC1 is a significant marker protein expressed in macrophages following M2 polarization, underscoring its role as an essential signature within this pro-tumorigenic environment. 7–9 These findings suggest that MRC1 is deeply involved in immune system activation and may have potential predictive value. However, there is no pan-cancer analysis available that delineates the value of MRC1 across a spectrum of diverse tumors in detail. In this study, we analyzed the expression of MRC1 in various cancer types and its relationship to prognosis using online datasets. Then, we explored the relationship between MRC1 expression and immune cell infiltration, immune scores, and immune checkpoint molecules. Finally, we estimated the potential predictive value of MRC1 immunotherapy by analyzing the relationship between MRC1 expression and current predictive biomarkers. Normal tissue datasets were obtained from the Genotype-Tissue Expression (GTEx) database, tumor cell line datasets were extracted from the Cancer Cell Line Encyclopedia (CCLE), and tumor tissue and para-cancerous tissue datasets were downloaded from The Cancer Genome Atlas (TCGA). All human e -Abstract Truncated-
medicine, general & internal